Citation

Barbui C, Patten SB. Epidemiol. Psychiatr. Sci. 2014; 23(4): 329-331.

Affiliation

Department of Community Health Sciences,Faculty of Medicine,University of Calgary,Calgary,Alberta,Canada.

Copyright

(Copyright © 2014, Cambridge University Press)

DOI

10.1017/S2045796014000456

PMID

25017037

Abstract

Although the mechanism by which antidepressants (ADs) may increase the risk of suicide-related outcomes is unknown, it has been hypothesised that some adverse effects, including akathisia, insomnia and panic attacks, as well as an early energising effect that might allow patients with depression to act on suicidal impulses, may have a key role. Considering that these adverse effects are dose-related, it might be hypothesised that the risk of suicidal behaviour is similarly related to the AD dose. This research question has recently been addressed by a propensity score-matched observational cohort study that involved 162 625 patients aged 10-64 years with a depression diagnosis who initiated therapy with citalopram, sertraline or fluoxetine. In this commentary, we discuss the main findings of this study in view of its methodological strengths and limitations, and we suggest possible implications for day-to-day clinical practice.

Language: en